通过β-catenin/Foxo复合体重定向TGF-β信号可预防肾脏纤维化
研究提出通过抑制β-catenin/TCF转录、增强β-catenin/Foxo1相互作用来重定向TGF-β信号,从而在保留抗炎作用的同时抑制纤维化。体外实验显示ICG-001增加Foxp3表达及Foxo1与Foxp3启动子结合;小鼠模型中rhTGF-β1联合ICG-001促进Treg扩增,减轻单侧输尿管梗阻和缺血再灌注损伤肾脏的炎症与纤维化,并预防远处器官纤维化。
要点
- 抑制β-catenin/TCF可重定向TGF-β信号至β-catenin/Foxo1,增强iTreg抗炎作用。
- rhTGF-β1联合ICG-001在UUO和IRI模型中减轻肾脏炎症与纤维化。
- 靶向β-catenin/Foxo可能是治疗纤维化疾病的新策略。
核心结论
- 将β-catenin从TCF介导转录转向Foxo介导转录,可抑制TGF-β的促纤维化效应并增强其抗炎效应。
研究设计与样本
- 体外使用EL4 T细胞来源的iTregs,经重组人TGF-β1处理并抑制β-catenin/TCF转录。
- 体内使用Foxp3gfp Ly5.1/5.2小鼠进行T细胞命运追踪,并在单侧输尿管梗阻和缺血再灌注损伤肾脏纤维化模型中评估联合治疗。
主要发现
- 在rhTGF-β1处理的iTregs中,ICG-001增加Foxp3表达、β-catenin与Foxo1相互作用、Foxo1与Foxp3启动子结合及Foxo转录活性。
- β-catenin表达水平与Foxo1结合Foxp3启动子水平及Foxo转录活性正相关。
- Foxp3gfp Ly5.1/5.2小鼠中,rhTGF-β1联合ICG-001较单用rhTGF-β1进一步促进iTregs和自然Tregs扩增。
- 在单侧输尿管梗阻和缺血再灌注损伤模型中,联合治疗增加Treg数量并减轻肾脏炎症和纤维化。
- ICG-001可预防rhTGF-β1引起的远处器官(肺和肝)纤维化。
临床怎么用
- 靶向β-catenin/Foxo复合体可能成为治疗纤维化疾病的新策略,但尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TGF-β is a key profibrotic factor, but targeting TGF-β to prevent fibrosis also abolishes its protective anti-inflammatory effects. Here, we investigated the hypothesis that we can redirect TGF-β signaling by preventing downstream profibrotic interaction of β-catenin with T cell factor (TCF), thereby enhancing the interaction of β-catenin with Foxo, a transcription factor that controls differentiation of TGF-β induced regulatory T cells (iTregs), and thus, enhance anti-inflammatory effects of TGF-β In iTregs derived from EL4 T cells treated with recombinant human TGF-β1 (rhTGF-β1) in vitro, inhibition of β-catenin/TCF transcription with ICG-001 increased Foxp3 expression, interaction of β-catenin and Foxo1, binding of Foxo1 to the Foxp3 promoter, and Foxo transcriptional activity. Moreover, the level of β-catenin expression positively correlated with the level of Foxo1 binding to the Foxp3 promoter and Foxo transcriptional activity. T cell fate mapping in Foxp3gfp Ly5.1/5.2 mice revealed that coadministration of rhTGF-β1 and ICG-001 further enhanced the expansion of iTregs and natural Tregs observed with rhTGF-β1 treatment alone. Coadministration of rhTGF-β1 with ICG-001 also increased the number of Tregs and reduced inflammation and fibrosis in the kidney fibrosis models of unilateral ureteric obstruction and ischemia-reperfusion injury. Notably, ICG-001 prevented the fibrosis in distant organs (lung and liver) caused by rhTGF-β1. Together, our results show that diversion of β-catenin from TCF- to Foxo-mediated transcription inhibits the β-catenin/TCF-mediated profibrotic effects of TGF-β while enhancing the β-catenin/Foxo-mediated anti-inflammatory effects. Targeting β-catenin/Foxo may be a novel therapeutic strategy in the treatment of fibrotic diseases that lead to organ failure.
引用
- Qiao X, Rao P, Zhang Y, et al. Redirecting TGF-β Signaling through the β-Catenin/Foxo Complex Prevents Kidney Fibrosis. J Am Soc Nephrol. 2017. PMID: 29180394. doi:10.1681/ASN.2016121362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。